Inductos

Dibotermin alfa, the active ingredient in Inductos, is a recombinant human bone morphogenetic protein-2 presented as an implant for implantation use. It promotes bone formation in patients undergoing spinal fusion surgery, bone defect repair, or treatment of non-union fractures.

GNH USA supplies Inductos as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide, providing regulatory‑approved products for surgical orthopaedic applications.

Inductos (dibotermin alfa) is employed in orthopedic and spinal surgical procedures to stimulate osteogenesis.

Spinal fusion surgery: enhances vertebral segment fusion and stability, reducing the risk of pseudo‑arthrosis. Bone defect repair: stimulates new bone growth in critical-sized defects, facilitating structural restoration. Non‑union fractures: promotes healing of fractures that have failed to unite, improving functional recovery.

Inductos may be associated with local and systemic adverse reactions following implantation.

Common Side Effects: - Local inflammation at the implant site, presenting as redness or mild swelling. - Peri‑incisional edema, often transient and self‑limiting. - Seroma or wound drainage, typically resolving with routine postoperative care.

Serious or Rare Side Effects: - Ectopic bone formation in adjacent soft tissues, which may require surgical revision. - Severe infection or osteomyelitis at the implantation site. - Allergic or hypersensitivity reaction, potentially leading to anaphylaxis.

Prior to using Inductos, clinicians should consider several safety measures.

Patient selection: assess for active infection or malignancy at the surgical site. Surgical technique: ensure accurate placement to avoid ectopic bone formation. Concomitant medications: avoid high‑dose NSAIDs that may impair bone healing. Monitoring: observe for signs of infection, excessive swelling, or abnormal bone growth. Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are lacking. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Dibotermin alfa may interact with certain systemic therapies that affect bone metabolism.

Major Interactions (Avoid): - Systemic corticosteroids: may suppress the osteogenic response. - Chemotherapeutic agents: can inhibit new bone formation. - Radiation therapy to the implantation site: reduces BMP‑2 efficacy.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish bone healing if used long term. - Anticoagulants: increase risk of postoperative bleeding at the implant site. - Bisphosphonates: potential interference with bone remodeling processes.